Skip to main content
. 2020 Jun 9;10:9329. doi: 10.1038/s41598-020-66319-9

Table 4.

Non-manifesting carriers’ characteristics.

Control LRRK2-NMC GBA-NMC Significance
# 196 55 97
Age (y) 54.57 (11.32) 52.89 (10.58) 54.27 (9.59) 0.517
Sex m/f 89/107 28/27 36/61 0.377
Orthostatic Hypotension (%) 7% 10.09% 10.30% 0.516
MDS-UPDRS 5.46 (4.35) 5.69 (4.31) 6.06 (6.79) 0.449
MoCA 26.46 (2.77) 26.43 (2.74) 25.86 (3.27) 0.308
UPSIT 30.39 (6.82) 31.42 (4.93) 29.45 (6.89) 0.163
RBDQ 1.75 (1.67) 1.42 (1.57) 1.98 (1.96) 0.281
NMSQ 3.39 (3.48) 2.75 (2.78) 3.35 (3.58) 0.699
SCOPA-AUT 8.42 (7.22) 7.98 (5.96) 8.47 (7.90) 0.252
BDI 4.16 (5.26) 3.61 (4.70) 4.22 (5.65) 0.304
Probability of prodromal PD (%) 10.95 (20.17) 33.83 (31.54)@ 16.09 (25.70) 0.001

NMC- Non-Manifesting Carriers, m-male, f-female, MDS-UPDRS- Movement Disorder Society - Unified Parkinson’s Disease Rating Scale, MoCA – Montreal Cognitive Assessment, UPSIT- University of Pennsylvania Smell Identification Test, RBDQ- REM sleep Behavior Disorder Questionnaire, NMSQ- Non-Motor Symptoms questionnaire, SCOPA-AUT- Scale of Outcome in Parkinson’s Disease – Autonomic Dysfunction, BDI- Beck Depression Inventory.

@Differences between LRRK2-NMC and GBA-NMC, control.